Solmaz Ece Yilmaz* and Ayse Gunes-Bayir

Bezmialem Vakif University, Faculty of Health Sciences, Department of Nutrition and Dietetics, Eyüpsultan, Istanbul, Turkey

*Corresponding Author: Solmaz Ece Yilmaz, Bezmialem Vakif University, Faculty of Health Sciences, Department of Nutrition and Dietetics, Eyüpsultan, Istanbul, Turkey.

Received: December 24, 2021; Published: January 31, 2022

Abstract

Background: Irritable Bowel Syndrome (IBS) is one of the common intestinal diseases reducing quality of life. Its global prevalence varies between 7 - 21%. Changes in intestinal microbiome, permeability, immune function, motility and visceral sensitivity, brain-intestinal interactions and psychosocial status are suggested to be effective in the pathogenesis of IBS. Variability of symptoms in IBS including chronic abdominal pain with diarrhea or constipation separately or both resulted in different strategies to be carried out in the treatment of the disease.

Summary: In the treatment of IBS patients, a holistic approach consisting of diet, lifestyle changes and drugs is required. Recent studies shown that vitamin D deficiency is common in IBS patients and supplementation of vitamin D can be effective in the treatment of IBS. The immunomodulatory, anti-inflammatory and antimicrobial properties of vitamin D and its association with psychosocial status are related to its role in IBS. Since IBS is a stress-sensitive disorder, impact of SARS-CoV-2 infection on IBS symptoms can not be ignored. In addition, IBS patients have a high risk of vitamin D deficiency resulting more severe symptoms during the pandemic. In this study, the role of vitamin D in IBS and the impact of SARS-CoV-2 infection in IBS patients were reviewed.

Key points: The intervention studies on vitamin D supplementation do not provide strong and generalizable evidence. SARS-CoV-2 infection could effect IBS symptoms. Vitamin D supplementation may be effective for IBS patients during COVID-19 pandemic since IBS patients are prone to infection and have a risk of more severe symptoms.

Keywords: Irritable Bowel Syndrome; Vitamin D; Vitamin D Deficiency; Microbiota; SARS-COV-2 Infection

References

Chey WD., et al. “Irritable Bowel Syndrome: A Clinical Review”.JAMA9 (2015): 949-958.
1. Schoenfeld PS. “Advances in IBS 2016: A Review of Current and Emerging Data”. Gastroenterol Hepatol (NY)8.3 (2016): 1‐11.
2. Ford AC., et al. “ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome”. The American Journal of Gastroenterology2 (2018): 1-18.
3. Jerndal P., et al. “Gastrointestinal‐specific anxiety: an important factor for severity of GI symptoms and quality of life in IBS”. Neurogastroenterology and Motility 22 (2010): 646-e179.
4. DeLuca HF. “Overview of general physiologic features and functions of vitamin D”. The American Journal of Clinical Nutrition6 (2004): 1689-1696.
5. Williams CE., et al. “Vitamin D status in irritable bowel syndrome and the impact of supplementation on symptoms: what do we know and what do we need to know?” European Journal of Clinical Nutrition10 (2018): 1358-1363.
6. El Amrousy D., et al. “Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial”. Saudi J Gastroenterol2 (2018): 109‐114.
7. Barbalho SM., et al. “Irritable bowel syndrome: a review of the general aspects and the potential role of vitamin D”. Expert Review of Gastroenterology and Hepatology4 (2019): 345-359.
8. Romano CM., et al. “Past, present, and future of COVID-19: a review”. Brazilian Journal of Medical and Biological Research9 (2020): e10475.
9. Quek S., et al. “Impact of the coronavirus disease 2019 pandemic on irritable bowel syndrome”. Journal of Gastroenterology and Hepatology8 (2021): 2187-2197.
10. Vodnar DC., et al. “Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota”. Frontiers in Cellular and Infection Microbiology 10 (2020): 575559.
11. Ali N. “Role of vitamin D in preventing of COVID-19 infection, progression and severity”. Journal of Infection and Public Health 13.10 (2020): 1373-1380.
12. Black CJ and Ford AC. “Global burden of irritable bowel syndrome: trends, predictions and risk factors”. Nature Reviews. Gastroenterology and Hepatology8 (2020): 473-486.
13. Radovanovic-Dinic B., et al. “Irritable bowel syndrome - from etiopathogenesis to therapy”. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia1 (2018): 1-9.
14. Defrees DN and Bailey J. “Irritable Bowel Syndrome: Epidemiology, Pathophysiology, Diagnosis, and Treatment”. Primary Care4 (2017): 655-671.
15. Altobelli E., et al. “Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis”. Nutrients9 (2017): 940.
16. Hadjivasilis A., et al. “New insights into irritable bowel syndrome: from pathophysiology to treatment”. Annals of Gastroenterology 6 (2019): 554-564.
17. Zhou Q and Verne GN. “New insights into visceral hypersensitivity--clinical implications in IBS”. Nature reviews. Gastroenterology and Hepatology 6 (2011): 349-355.
18. Moayyedi P., et al. “Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS)”. Journal of the Canadian Association of Gastroenterology1 (2019): 6-29.
19. Jalili M., et al. “Effects of Vitamin D Supplementation in Patients with Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial”. International Journal of Preventive Medicine 10 (2019): 16.
20. Shang M and Sun J. “Vitamin D/VDR, Probiotics, and Gastrointestinal Diseases”. Current Medicinal Chemistry9 (2017): 876-887.
21. Sun J. “Dietary vitamin D, vitamin D receptor, and microbiome”. Current Opinion in Clinical Nutrition and Metabolic Care6 (2018): 471-474.
22. Prietl B., et al. “Vitamin D and immune function”. Nutrients7 (2013): 2502-2521.
23. Khalighi SM., et al. “Effects of vitamin D3 supplementation on clinical symptoms, quality of life, serum serotonin (5-hydroxytryptamine), 5-hydroxy-indole acetic acid, and ratio of 5-HIAA/5-HT in patients with diarrhea-predominant irritable bowel syndrome: A randomized clinical trial”. EXCLI Journal 19 (2020): 652-667.
24. Kerr DC., et al. “Associations between vitamin D levels and depressive symptoms in healthy young adult women”. Psychiatry Research1 (2015): 46‐51.
25. Dussik CM., et al. “Gene Expression Profiling and Assessment of Vitamin D and Serotonin Pathway Variations in Patients With Irritable Bowel Syndrome”. Journal of Neurogastroenterology and Motility1 (2018): 96-106.
26. Holick MF and Chen TC. “Vitamin D deficiency: a worldwide problem with health consequences”. The American Journal of Clinical Nutrition4 (2008): 1080S-1086S.
27. Holick MF. “Vitamin D deficiency”. New England Journal of Medicine 357 (2007): 266-281.
28. Amrein K., et al. “Vitamin D deficiency 2.0: an update on the current status worldwide”. European Journal of Clinical Nutrition11 (2020): 1498-1513.
29. Holick MF., et al. “Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline”. The Journal of clinical endocrinology and metabolism7 (2011): 1911-1930.
30. Institute of Medicine (US) Committee to Review “Dietary Reference Intakes for Vitamin D” and Calcium, Ross AC, Taylor CL, Yaktine AL, Del Valle HB (eds) Dietary Reference Intakes for Calcium and Vitamin D”. National Academies Press (US) (2011).
31. Khayyat Y and Attar S. “Vitamin D Deficiency in Patients with Irritable Bowel Syndrome: Does it Exist?” Oman Medical Journal2 (2015): 115-118.
32. Abbasnezhad A., et al. “Association of Serum Vitamin D Concentration With Clinical Symptoms and Quality of Life in Patients With Irritable Bowel Syndrome”. Journal of the American College of Nutrition4 (2019): 327-333.
33. Nwosu BU., et al. “Vitamin D status in pediatric irritable bowel syndrome”. PloS One2 (2017): e0172183.
34. Khayyatzadeh SS., et al. “Serum Transaminase Concentrations and the Presence of Irritable Bowel Syndrome Are Associated with Serum 25-Hydroxy Vitamin D Concentrations in Adolescent Girls Who Are Overweight and Obese”. Annals of Nutrition and Metabolism3-4 (2017): 234-241.
35. Lamberg-Allardt C. “Vitamin D in foods and as supplements”. Progress in Biophysics and Molecular Biology1 (2006): 33-38.
36. Abbasnezhad A., et al. “Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients: a randomized double-blind clinical trial. Neurogastroenterology and motility”. The official journal of the European Gastrointestinal Motility Society10 (2016): 1533-1544.
37. Jalili M., et al. “Co-Administration of Soy Isoflavones and Vitamin D in Management of Irritable Bowel Disease”. PloS One8 (2016): e0158545.
38. Jalili M., et al. “Soy isoflavones and cholecalciferol reduce inflammation, and gut permeability, without any effect on antioxidant capacity in irritable bowel syndrome: A randomized clinical trial”. Clinical Nutrition ESPEN 34 (2019): 50-54.
39. Sprake EF., et al. “Vitamin D3 as a novel treatment for irritable bowel syndrome: single case leads to critical analysis of patient-centred data”. BMJ Case Reports (2012).
40. Amani R., et al. “Vitamin D3 Induced Decrease in IL-17 and Malondialdehyde, and Increase in IL-10 and Total Antioxidant Capacity Levels in Patients with Irritable Bowel Syndrome”. Iranian Journal of Immunology: IJI3 (2018): 186-196.
41. Tazzyman S., et al. “Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: outcomes from a pilot trial”. BMJ Open Gastroenterology 2 (2015): e000052.
42. Abboud M., et al. “The Health Effects of Vitamin D and Probiotic Co-Supplementation: A Systematic Review of Randomized Controlled Trials”. Nutrients1 (2020): 111.
43. Oshima T., et al. “Impacts of the COVID2019 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey”. Journal of Gastroenterology and Hepatology Advance online publication7 (2020): 1820-1827.
44. Shah S., et al. “Prevalence, Psychological Responses and Associated Correlates of Depression, Anxiety and Stress in a Global Population, During the Coronavirus Disease (COVID-19) Pandemic”. Community Mental Health Journal1 (2021): 101-110.
45. Alzahrani MA., et al. “Coronavirus disease 2019 pandemic stress and its effects on irritable bowel syndrome patients in Saudi Arabia”. Medicine51 (2020): e23711.
46. Kamp KJ., et al. “Impact of COVID-19 on Individuals With Irritable Bowel Syndrome and Comorbid Anxiety and/or Depression”. Journal of Clinical Gastroenterology Advance online publication (2021).
47. Kopczyńska M., et al. “Quality of life and depression in patients with irritable bowel syndrome”. Przeglad Gastroenterologiczny2 (2018): 102-108.
48. Weir EK., et al. “Does vitamin D deficiency increase the severity of COVID-19?” Clinical Medicine (London, England)4 (2020): e107-e108.

Citation

Citation: Solmaz Ece Yilmaz and Ayse Gunes-Bayir. “The Role of Vitamin D and the Impact of SARS-CoV-2 Infection in Irritable Bowel Syndrome Patients". Acta Scientific Nutritional Health 6.2 (2022): 103-111.

Copyright

Copyright: © 2022 Solmaz Ece Yilmaz and Ayse Gunes-Bayir. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.